Cargando…

Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?

Preclinical and clinical studies have shown that prior receipt of radiotherapy enhances antitumor immune responses, a phenomenon we call the “radio-memory effect.” However, all of the evidence regarding this effect to date comes from work with PD1/PDL1 inhibitors. Here we explored whether this effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dawei, Song, Xinyu, Wang, Haiyong, Gao, Zhenwu, Meng, Wenjuan, Chen, Shuquan, Ma, Yunfeng, Wang, Youda, Li, Kong, Yu, Jinming, Yue, Jinbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297715/
https://www.ncbi.nlm.nih.gov/pubmed/30619280
http://dx.doi.org/10.3389/fimmu.2018.02916
_version_ 1783381188775247872
author Chen, Dawei
Song, Xinyu
Wang, Haiyong
Gao, Zhenwu
Meng, Wenjuan
Chen, Shuquan
Ma, Yunfeng
Wang, Youda
Li, Kong
Yu, Jinming
Yue, Jinbo
author_facet Chen, Dawei
Song, Xinyu
Wang, Haiyong
Gao, Zhenwu
Meng, Wenjuan
Chen, Shuquan
Ma, Yunfeng
Wang, Youda
Li, Kong
Yu, Jinming
Yue, Jinbo
author_sort Chen, Dawei
collection PubMed
description Preclinical and clinical studies have shown that prior receipt of radiotherapy enhances antitumor immune responses, a phenomenon we call the “radio-memory effect.” However, all of the evidence regarding this effect to date comes from work with PD1/PDL1 inhibitors. Here we explored whether this effect also occurs with other forms of immune therapy, specifically interleukin-2 (IL-2). We retrospectively assessed outcomes in patients with malignant pleural effusion (MPE) who had previously received radiotherapy for non-small-cell lung cancer (NSCLC) within 18 months before the intrapleural infusion of IL-2 or cisplatin. Radiotherapy sites included lungs, thoracic lymph nodes, and intracranial. All patients received intrapleural infusion of IL-2 or cisplatin, and most had had several cycles of standard chemotherapy for NSCLC. We identified 3,747 patients with MPE (median age 64 years [range 29–88)) treated at one of several institutions from August 2009 through February 2015; 642 patients had been treated with IL-2 and 1102 with cisplatin and had survived for at least 6 months afterward. Among those who received IL-2, 288 had no radiotherapy, 324 had extracranial (i.e., thoracic) radiotherapy, and 36 had intracranial radiotherapy. The median follow-up time for surviving patients was 38 months. Patients who had received extracranial radiotherapy followed by IL-2 had significantly longer PFS than patients who had not received extracranial radiotherapy (i.e., either no radiotherapy or intracranial radiotherapy). Patients who had received intracranial or extracranial radiotherapy followed by IL-2 had significantly longer OS than did other patients. No survival advantage was noted for prior radiotherapy among patients who received intrapleural cisplatin. We speculate that previous radiotherapy could enhance the efficacy of subsequent intrapleural infusion of IL-2, a “radio-memory” effect that could be beneficial in future studies.
format Online
Article
Text
id pubmed-6297715
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62977152019-01-07 Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect? Chen, Dawei Song, Xinyu Wang, Haiyong Gao, Zhenwu Meng, Wenjuan Chen, Shuquan Ma, Yunfeng Wang, Youda Li, Kong Yu, Jinming Yue, Jinbo Front Immunol Immunology Preclinical and clinical studies have shown that prior receipt of radiotherapy enhances antitumor immune responses, a phenomenon we call the “radio-memory effect.” However, all of the evidence regarding this effect to date comes from work with PD1/PDL1 inhibitors. Here we explored whether this effect also occurs with other forms of immune therapy, specifically interleukin-2 (IL-2). We retrospectively assessed outcomes in patients with malignant pleural effusion (MPE) who had previously received radiotherapy for non-small-cell lung cancer (NSCLC) within 18 months before the intrapleural infusion of IL-2 or cisplatin. Radiotherapy sites included lungs, thoracic lymph nodes, and intracranial. All patients received intrapleural infusion of IL-2 or cisplatin, and most had had several cycles of standard chemotherapy for NSCLC. We identified 3,747 patients with MPE (median age 64 years [range 29–88)) treated at one of several institutions from August 2009 through February 2015; 642 patients had been treated with IL-2 and 1102 with cisplatin and had survived for at least 6 months afterward. Among those who received IL-2, 288 had no radiotherapy, 324 had extracranial (i.e., thoracic) radiotherapy, and 36 had intracranial radiotherapy. The median follow-up time for surviving patients was 38 months. Patients who had received extracranial radiotherapy followed by IL-2 had significantly longer PFS than patients who had not received extracranial radiotherapy (i.e., either no radiotherapy or intracranial radiotherapy). Patients who had received intracranial or extracranial radiotherapy followed by IL-2 had significantly longer OS than did other patients. No survival advantage was noted for prior radiotherapy among patients who received intrapleural cisplatin. We speculate that previous radiotherapy could enhance the efficacy of subsequent intrapleural infusion of IL-2, a “radio-memory” effect that could be beneficial in future studies. Frontiers Media S.A. 2018-12-11 /pmc/articles/PMC6297715/ /pubmed/30619280 http://dx.doi.org/10.3389/fimmu.2018.02916 Text en Copyright © 2018 Chen, Song, Wang, Gao, Meng, Chen, Ma, Wang, Li, Yu and Yue. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chen, Dawei
Song, Xinyu
Wang, Haiyong
Gao, Zhenwu
Meng, Wenjuan
Chen, Shuquan
Ma, Yunfeng
Wang, Youda
Li, Kong
Yu, Jinming
Yue, Jinbo
Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?
title Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?
title_full Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?
title_fullStr Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?
title_full_unstemmed Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?
title_short Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?
title_sort previous radiotherapy increases the efficacy of il-2 in malignant pleural effusion: potential evidence of a radio-memory effect?
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297715/
https://www.ncbi.nlm.nih.gov/pubmed/30619280
http://dx.doi.org/10.3389/fimmu.2018.02916
work_keys_str_mv AT chendawei previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT songxinyu previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT wanghaiyong previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT gaozhenwu previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT mengwenjuan previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT chenshuquan previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT mayunfeng previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT wangyouda previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT likong previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT yujinming previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect
AT yuejinbo previousradiotherapyincreasestheefficacyofil2inmalignantpleuraleffusionpotentialevidenceofaradiomemoryeffect